
Release date: 2026-02-03 17:11:22 Article From: Lucius Laos Recommended: 8
Nintedanib is a multi-targeted tyrosine kinase inhibitor; it can reduce the activity of fibroblasts in patients with idiopathic pulmonary fibrosis (IPF).
Attend regular follow-up appointments to allow your medical team to monitor the progression of your condition. Inform your medical team if your symptoms do not start to improve or worsen. Blood tests may be required while you are taking this medication.
Drink plenty of water during the administration of this medication. Consult your medical team if you experience diarrhoea, nausea and vomiting. Excessive fluid loss may make taking this medication dangerous for you.
If you smoke and notice that this medication is not working well for you, inform your medical team. If you decide to quit smoking, discuss it with your medical team.
This medication may increase your risk of bruising or bleeding. Call your medical team if you notice any unusual bleeding.
If you plan to become pregnant or think you may be pregnant, consult your medical team. Taking this medication during pregnancy and within 3 months after stopping treatment may cause severe birth defects. A negative pregnancy test is required before starting this medication. If you become pregnant, miss a menstrual period or stop using contraception, stop taking this medication and call your medical team immediately.
Store it in a place out of the reach of children and pets.
Store at room temperature between 20 and 25 degrees Celsius (68 and 77 degrees Fahrenheit). Avoid exposure to extreme heat. Protect from moisture. Keep the container tightly closed. Dispose of any unused medication after the expiration date.
Return the medication through a drug take-back programme. Consult your pharmacy or law enforcement agency to find a take-back location.
If the medication cannot be returned, check the label or package insert to confirm whether it should be thrown in the trash or flushed down the toilet. If you are unsure, consult your medical team. If it is confirmed safe to dispose of in the trash, pour the medication out of its container. Mix the medication with cat litter, soil, coffee grounds or other unwanted substances. Seal the mixture in a bag or container and then place it in the trash.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:802025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3732024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:712025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:932025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:872025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1022025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:992025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:992025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: